Published in Clin Infect Dis on June 09, 2005
Hepatitis C seroprevalence among prison inmates since 2001: still high but declining. Public Health Rep (2014) 1.55
Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology (2015) 1.44
Prevalence and correlates of hepatitis C infection among male injection drug users in detention, Tehran, Iran. J Urban Health (2009) 1.28
Prevalence of HIV and hepatitis C virus infections among inmates of Quebec provincial prisons. CMAJ (2007) 1.27
Prevalence of infection with hepatitis B and C viruses and co-infection with HIV in three jails: a case for viral hepatitis prevention in jails in the United States. J Urban Health (2008) 1.17
Hepatitis C among clients of health care for the homeless primary care clinics. J Health Care Poor Underserved (2012) 1.07
Hepatitis C virus in pregnancy. Am J Perinatol (2013) 1.03
Prisons as social determinants of hepatitis C virus and tuberculosis infections. Public Health Rep (2010) 1.02
HCV-related mortality among male prison inmates in Texas, 1994-2003. Ann Epidemiol (2009) 1.02
Social determinants of health associated with hepatitis C co-infection among people living with HIV: results from the Positive Spaces, Healthy Places study. Open Med (2011) 0.98
Prevalence, genotypes and factors associated with HCV infection among prisoners in Northeastern Brazil. World J Gastroenterol (2011) 0.98
Prevalence of hepatitis C infection in New York City, 2004. J Urban Health (2009) 0.96
A simple strategy to identify acute hepatitis C virus infection among newly incarcerated injection drug users. Hepatology (2013) 0.96
Estimating the prevalence of hepatitis C infection in New York City using surveillance data. Epidemiol Infect (2013) 0.93
Promoting HCV treatment completion for prison inmates: New York State's hepatitis C continuity program. Public Health Rep (2007) 0.92
Hepatitis C and B prevalence in Spanish prisons. Eur J Clin Microbiol Infect Dis (2011) 0.91
Access to treatment of hepatitis C in prison inmates. Dig Dis Sci (2008) 0.89
Epidemiological aspects of HCV infection in non-injecting drug users in the Brazilian state of Pará, eastern Amazon. Virol J (2014) 0.88
Prevalence and incidence of hepatitis C virus infection among Aboriginal young people who use drugs: results from the Cedar Project. Open Med (2009) 0.88
Influence of healthcare-associated factors on the efficacy of hepatitis C therapy. ScientificWorldJournal (2012) 0.86
Chronic liver disease mortality among male prison inmates in Texas, 1989-2003. Am J Gastroenterol (2009) 0.86
Estimating HCV prevalence at the state level: a call to increase and strengthen current surveillance systems. Am J Public Health (2013) 0.85
Correlates of incarceration among young methamphetamine users in Chiang Mai, Thailand. Am J Public Health (2008) 0.84
Comparison of risk-based hepatitis C screening and the true seroprevalence in an urban prison system. J Urban Health (2015) 0.80
Viral hepatitis in Hawai'i--differing perspectives. Hawaii Med J (2010) 0.78
Vaccinations in prisons: A shot in the arm for community health. Hum Vaccin Immunother (2015) 0.77
Hepatitis C Infection Among Hispanics in California. J Addict Dis (2015) 0.75
The Prevalence of HIV Risk Behaviors among Felony Drug Court Participants. Drug Court Rev (2012) 0.75
Prevalence and Incidence of HCV Infection among Prisoners in Central Brazil. PLoS One (2017) 0.75
Hepatitis C Prevalence Among Iranian Female prisoners. Hepat Mon (2012) 0.75
Controversies in and challenges to our understanding of hepatitis C. World J Gastroenterol (2007) 0.75
The societal cost of heroin use disorder in the United States. PLoS One (2017) 0.75
Risk factors for prevalent hepatitis C virus-infection among inmates in a state prison system in Mexico. PLoS One (2017) 0.75
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99
Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS (2003) 11.66
Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet (2010) 8.52
Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med (2004) 5.78
Maternal alloantigens promote the development of tolerogenic fetal regulatory T cells in utero. Science (2008) 5.76
Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS (2004) 4.64
Genome-wide and fine-resolution association analysis of malaria in West Africa. Nat Genet (2009) 4.30
Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin Infect Dis (2005) 4.27
Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis (2012) 4.24
Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA (2002) 4.02
Ten-year incidence of Chagas cardiomyopathy among asymptomatic Trypanosoma cruzi-seropositive former blood donors. Circulation (2013) 3.84
Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis (2002) 3.83
Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol (2011) 3.66
High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol (2011) 3.49
Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. Hepatology (2013) 3.35
Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med (2014) 3.24
Use of laboratory tests and clinical symptoms for identification of primary HIV infection. AIDS (2002) 3.22
A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis (2011) 3.10
Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol (2005) 3.09
Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Virol (2008) 2.90
Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis (2009) 2.82
Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol (2007) 2.58
The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion-related acute lung injury risk reduction strategy. Transfusion (2009) 2.56
Beyond detuning: 10 years of progress and new challenges in the development and application of assays for HIV incidence estimation. AIDS (2010) 2.43
Biospecimen repositories: are blood donors willing to participate? Transfusion (2010) 2.33
Modeling sequence evolution in acute HIV-1 infection. J Theor Biol (2009) 2.32
The consequences of temporary deferral on future whole blood donation. Transfusion (2007) 2.31
Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus. Transfusion (2008) 2.27
Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis (2013) 2.23
Development of a new less-sensitive enzyme immunoassay for detection of early HIV-1 infection. J Acquir Immune Defic Syndr (2003) 2.21
Tregs control the development of symptomatic West Nile virus infection in humans and mice. J Clin Invest (2009) 2.18
Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis (2013) 2.17
A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology (2007) 2.16
Clearance of hepatitis C virus RNA from the peripheral blood mononuclear cells of blood donors who spontaneously or therapeutically control their plasma viremia. Hepatology (2008) 2.14
The detection of acute HIV infection. J Infect Dis (2010) 2.14
Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol (2006) 2.12
Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers. PLoS Pathog (2013) 2.06
Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race. Hepatology (2006) 2.03
The impact of male-to-male sexual experience on risk profiles of blood donors. Transfusion (2005) 2.02
WHO guidelines on fluid resuscitation in children: missing the FEAST data. BMJ (2014) 2.00
Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion. Transfusion (2009) 2.00
Frequency of HBV DNA detection in US blood donors testing positive for the presence of anti-HBc: implications for transfusion transmission and donor screening. Transfusion (2003) 2.00
The ATHENA human papillomavirus study: design, methods, and baseline results. Am J Obstet Gynecol (2011) 1.93
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol (2006) 1.92
The whole is greater than the sum of its parts: hemostatic profiles of whole blood variants. J Trauma Acute Care Surg (2014) 1.88
The cost-effectiveness of screening the U.S. blood supply for West Nile virus. Ann Intern Med (2005) 1.88
Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7. PLoS Pathog (2012) 1.88
Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology (2002) 1.88
Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells. J Infect Dis (2012) 1.86
Quantitative estimate of the risks and benefits of possible alternative blood donor deferral strategies for men who have had sex with men. Transfusion (2009) 1.85
Donation archives and prospective donor-recipient repositories: indispensable tools for monitoring blood safety. Transfusion (2007) 1.85
Prevalence, incidence, and residual risk of human immunodeficiency virus among community and replacement first-time blood donors in São Paulo, Brazil. Transfusion (2005) 1.84
Elevations in IL-10, TNF-alpha, and IFN-gamma from the earliest point of HIV Type 1 infection. AIDS Res Hum Retroviruses (2006) 1.83
Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med (2013) 1.82
High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection. J Virol (2009) 1.82
The interplay of age stratification and HPV testing on the predictive value of ASC-US cytology. Results from the ATHENA HPV study. Am J Clin Pathol (2012) 1.79
Prevalence of HIV-1 in blood donations following implementation of a structured blood safety policy in South Africa. JAMA (2006) 1.78
Prevalence of diabetic retinopathy in various ethnic groups: a worldwide perspective. Surv Ophthalmol (2012) 1.76
ACAT2 is localized to hepatocytes and is the major cholesterol-esterifying enzyme in human liver. Circulation (2004) 1.76
Young women engaged in sex work in Phnom Penh, Cambodia, have high incidence of HIV and sexually transmitted infections, and amphetamine-type stimulant use: new challenges to HIV prevention and risk. Sex Transm Dis (2011) 1.74
Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis. Hepatology (2002) 1.72
Dynamics of viremia in early hepatitis C virus infection. Transfusion (2005) 1.72
Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results. Am J Clin Pathol (2011) 1.72
Testing strategy to identify cases of acute hepatitis C virus (HCV) infection and to project HCV incidence rates. J Clin Microbiol (2007) 1.70
Demographic profile of blood donors at three major Brazilian blood centers: results from the International REDS-II study, 2007 to 2008. Transfusion (2009) 1.68
Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc: implications for future HBV screening policy. Transfusion (2004) 1.67
Independent assessment of candidate HIV incidence assays on specimens in the CEPHIA repository. AIDS (2014) 1.67
The risk of hepatitis B virus infection by transfusion in Kumasi, Ghana. Blood (2002) 1.66
Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children. PLoS One (2009) 1.65
Seroreversion in subjects receiving antiretroviral therapy during acute/early HIV infection. Clin Infect Dis (2006) 1.65
Dengue viremia in blood donors from Honduras, Brazil, and Australia. Transfusion (2008) 1.62
Prevalence and quantitation of parvovirus B19 DNA levels in blood donors with a sensitive polymerase chain reaction screening assay. Transfusion (2007) 1.60
Absence of transfusion-associated microchimerism in pediatric and adult recipients of leukoreduced and gamma-irradiated blood components. Transfusion (2011) 1.59
A linked donor-recipient study to evaluate parvovirus B19 transmission by blood component transfusion. Blood (2009) 1.59
Age related macular degeneration. BMJ (2010) 1.59
Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals. AIDS (2010) 1.57
Failure to confirm XMRV/MLVs in the blood of patients with chronic fatigue syndrome: a multi-laboratory study. Science (2011) 1.56
Development and persistence of West Nile virus-specific immunoglobulin M (IgM), IgA, and IgG in viremic blood donors. J Clin Microbiol (2005) 1.56
Duration of red blood cell storage and survival of transfused patients (CME). Transfusion (2010) 1.53
Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS (2004) 1.53
Unifying the spatial epidemiology and molecular evolution of emerging epidemics. Proc Natl Acad Sci U S A (2012) 1.52
Genome-wide association study indicates two novel resistance loci for severe malaria. Nature (2012) 1.52
Human leukocyte antigen B*57 does not fully explain hepatitis C clearance in HIV controllers. AIDS (2013) 1.51
Enhanced ascertainment of microchimerism with real-time quantitative polymerase chain reaction amplification of insertion-deletion polymorphisms. Transfusion (2006) 1.50
Patient-care practices associated with an increased prevalence of hepatitis C virus infection among chronic hemodialysis patients. Infect Control Hosp Epidemiol (2011) 1.48
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol (2004) 1.47
Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). J Hepatol (2002) 1.43
A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers. PLoS One (2011) 1.43
Commercial sex work and risk of HIV infection among young drug-injecting men who have sex with men in San Francisco. Sex Transm Dis (2006) 1.43
Genetic diversity of recently acquired and prevalent HIV, hepatitis B virus, and hepatitis C virus infections in US blood donors. J Infect Dis (2012) 1.43
The role of transplacental microtransfusions of maternal lymphocytes in HIV transmission to newborns. AIDS (2008) 1.42
The Blood Xenotropic Murine Leukemia Virus-Related Virus Scientific Research Working Group: mission, progress, and plans. Transfusion (2011) 1.41
Seroprevalence of hepatitis C virus and hepatitis B virus among San Francisco injection drug users, 1998 to 2000. Hepatology (2007) 1.40
Predicting the clinical outcome of severe falciparum malaria in african children: findings from a large randomized trial. Clin Infect Dis (2012) 1.39